Key for crossing the BBB with nanoparticles: the rational design

Abstract

Central nervous system diseases are a heavy burden on society and health care systems. Hence, the delivery of drugs to the brain has gained more and more interest. The brain is protected by the blood–brain barrier (BBB), a selective barrier formed by the endothelial cells of the cerebral microvessels, which at the same time acts as a bottleneck for drug delivery by preventing the vast majority of drugs to reach the brain. To overcome this obstacle, drugs can be loaded inside nanoparticles that can carry the drug through the BBB. However, not all particles are able to cross the BBB and a multitude of factors needs to be taken into account when developing a carrier system for this purpose. Depending on the chosen pathway to cross the BBB, nanoparticle material, size and surface properties such as functionalization and charge should be tailored to fit the specific route of BBB crossing.

References 187

1. 1.

   World Health Organization. The top 10 causes of death.

   Not in our library

2. 2.
   Regenerative Medicine Therapies for Targeting Neuroinflammation After Stroke · 2018

   Not checked
3. 3.

   Abbott N J, Rönnbäck L, Hansson E. Nat Rev Neurosci. 2006;7:41-53.

   Not in our library10.1038/nrn1824

4. 4.

   Sweeney M D, Sagare A P, Zlokovic B V. Nat Rev Neurol. 2018;14:133-150.

   Not in our library10.1038/nrneurol.2017.188

5. 5.

   Abbott N J, Patabendige A A K, Dolman D E M, Yusof S R, Begley D J. Neurobiol Dis. 2010;37:13-25.

   Not in our library10.1016/j.nbd.2009.07.030

6. 6.

   Hawkins B T, Davis T P. Pharmacol Rev. 2005;57:173-185.

   Not in our library10.1124/pr.57.2.4

7. 7.

   Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. J Controlled Release. 2016;235:34-47.

   Not in our library10.1016/j.jconrel.2016.05.044

8. 8.

   Ballabh P, Braun A, Nedergaard M. Neurobiol Dis. 2004;16:1-13.

   Not in our library10.1016/j.nbd.2003.12.016

9. 9.

   Patel M M, Goyal B R, Bhadada S V, Bhatt J S, Amin A F. CNS Drugs. 2009;23:35-58.

   Not in our library10.2165/0023210-200923010-00003

10. 10.

    Chaichana K L, Pinheiro L, Brem H. Ther Delivery. 2015;6:353-369.

    Not in our library10.4155/tde.14.114

11. 11.

    Mistry A, Stolnik S, Illum L. Int J Pharm. 2009;379:146-157.

    Not in our library10.1016/j.ijpharm.2009.06.019

12. 12.

    Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Eur J Pharm Biopharm. 2018;128:337-362.

    Not in our library10.1016/j.ejpb.2018.05.009

13. 13.
    Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa · 2018

    No notice
14. 14.

    Erdő F, Bors L A, Farkas D, Bajza Á, Gizurarson S. Brain Res Bull. 2018;143:155-170.

    Not in our library10.1016/j.brainresbull.2018.10.009

15. 15.

    Agrawal M, Saraf S, Saraf S, Antimisiaris S G, Chougule M B, Shoyele S A, Alexander A. J Controlled Release. 2018;281:139-177.

    Not in our library10.1016/j.jconrel.2018.05.011

16. 16.

    Pires P C, Santos A O. J Controlled Release. 2018;270:89-100.

    Not in our library10.1016/j.jconrel.2017.11.047

17. 17.

    Lochhead J J, Thorne R G. Adv Drug Delivery Rev. 2012;64:614-628.

    Not in our library10.1016/j.addr.2011.11.002

18. 18.

    Blanchette M, Fortin D, Nag S. Blood-Brain Barrier Disruption in the Treatment of Brain Tumors. The Blood-Brain and Other Neural Barriers: Reviews and Protocols. 2011;447-463.

    Not in our library10.1007/978-1-60761-938-3_23

19. 19.

    Etame A B, Diaz R J, O'Reilly M A, Smith C A, Mainprize T G, Hynynen K, Rutka J T. Nanomedicine (N Y, NY, U S). 2012;8(7):1133-1142.

    Not in our library10.1016/j.nano.2012.02.003

20. 20.

    Bing K F, Howles G P, Qi Y, Palmeri M L, Nightingale K R. Ultrasound Med Biol. 2009;35:1298-1308.

    Not in our library10.1016/j.ultrasmedbio.2009.03.012

21. 21.

    Posadas I, Monteagudo S, Ceña V. Nanomedicine (London, U K). 2016;11:833-849.

    Not in our library10.2217/nnm.16.15

22. 22.

    European Commission. Definition - Nanomaterials.

    Not in our library

23. 23.

    Fattal E, Vauthier C. Drug Delivery: Nanoparticles. 2007;2:1183.

    Not in our library

24. 24.

    Kreuter J, Alyautdin R N, Kharkevich D A, Ivanov A A. Brain Res. 1995;674:171-174.

    Not in our library10.1016/0006-8993(95)00023-j

25. 25.

    Kreuter J. Adv Drug Delivery Rev. 2014;71:2-14.

    Not in our library10.1016/j.addr.2013.08.008

26. 26.

    Andrieux K, Couvreur P. Wiley Interdiscip Rev: Nanomed Nanobiotechnol. 2009;1:463-474.

    Not in our library10.1002/wnan.5

27. 27.

    Tapeinos C, Battaglini M, Ciofani G. J Controlled Release. 2017;264:306-332.

    Not in our library10.1016/j.jconrel.2017.08.033

28. 28.

    Ulbrich K, Knobloch T, Kreuter J. J Drug Targeting. 2011;19:125-132.

    Not in our library10.3109/10611861003734001

29. 29.

    Aghaie T, Jazayeri M H, Manian M, Khani L, Erfani M, Rezayi M, Ferns G A, Avan A. J Cell Biochem. 2019;120:2749-2755.

    Not in our library10.1002/jcb.27415

30. 30.

    Shevtsov M A, Nikolaev B P, Yakovleva L Y, Marchenko Y Y, Dobrodumov A V, Mikhrina A L, Martynova M G, Bystrova O A, Yakovenko I V, Ischenko A M. Int J Nanomed. 2014;9:273-287.

    Not in our library10.2147/ijn.s55118

31. 31.

    Sanchez-Covarrubias L, Slosky L M, Thompson B J, Davis T P, Ronaldson P T. Curr Pharm Des. 2014;20:1422-1449.

    Not in our library10.2174/13816128113199990463

32. 32.

    Banks W A, Owen J B, Erickson M A. Pharmacol Ther. 2012;136:82-93.

    Not in our library10.1016/j.pharmthera.2012.07.006

33. 33.

    Boado R J, Li J Y, Nagaya M, Zhang C, Pardridge W M. Proc Natl Acad Sci U S A. 1999;96:12079-12084.

    Not in our library10.1073/pnas.96.21.12079

34. 34.

    Zhang Z, Zhan C, Gao H, Gao X. Receptor-Mediated Transportation through BBB. Brain Targeted Drug Delivery System. 2019;105-128.

    Not in our library10.1016/b978-0-12-814001-7.00005-6

35. 35.

    Kim R B. Drug Metab Rev. 2002;34:47-54.

    Not in our library10.1081/dmr-120001389

36. 36.

    Mahringer A, Ott M, Reimold I, Reichel V, Fricker G. Curr Pharm Des. 2011;17:2762-2770.

    Not in our library10.2174/138161211797440221

37. 37.

    Miller D S. Trends Pharmacol Sci. 2010;31:246-254.

    Not in our library10.1016/j.tips.2010.03.003

38. 38.

    Chen R, Zhao X, Hu K, Gao H, Gao X. Efflux Pump Inhibition to Enhance Brain Targeting Delivery. Brain Targeted Drug Delivery System. 2019;185-196.

    Not in our library10.1016/b978-0-12-814001-7.00008-1

39. 39.
    Intracellular transport and regulation of transcytosis across the blood–brain barrier · 2018

    No notice
40. 40.
    Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges · 2019

    No notice

Cited by papers we hold 6

• Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier · 2024
  No notice
• Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology · 2022
  No notice
• Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy · 2021
  No notice
• Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? · 2021
  No notice
• Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges · 2021
  No notice
• Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.